KRAS and cancer: Previous study has shown that BRAF-mutated CMS1 phenotype and the KRAS-mutated CMS4 phenotype are the predominant phenotypes in SCC, whereas the CMS2 phenotype is almost exclusively present in CA, exhibiting activation of the WNT pathway (Fessler and Medema, 2016).